Medullary thyroid cancer: The functions of raf-1 and human achaete-scute homologue-1

Thyroid

Volumn 15, Issue 6, 2005, Pages 511-521

  Chen, Herbert ^a,b   Kunnimalaiyaan, Muthusamy ^a   Van Compel, Jamie J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CHROMOGRANIN A; DNA; ESTRADIOL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HELIX LOOP HELIX PROTEIN; HUMAN ACHAETE SCUTE HOMOLOGUE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UO 126;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA BINDING; EMBRYO; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; TUMOR GROWTH;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, MEDULLARY; ENZYME ACTIVATION; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTO-ONCOGENE PROTEINS C-RAF; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 22244454759     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.511     Document Type: Review

References (49)

1. Udelsman R, Chen H 1999 The current management of thyroid cancer. Adv Surg 33:1-27.
2. Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R, Bulkley GB 1998 Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 227:887-895.
3. Moley JF, Lairmore TC, Phay JE 1999 Hereditary endocrinopathies. Curr Prob Surg 36:653-762.
4. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH, Chung JH 2001 Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 11:73-8073-8800.
5. Kebebew E, Kikuchi S, Duh QY, Clark OH 2000 Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135:895-899.
6. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M 2000 Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Br J Cancer 83:715-718.
7. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Pong Y, Blumgart LH 1999 Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Intervent Radiol 10:397-403.
8. Isozaki T, Kiba T, Numata K, Saito S, Shimamura T, Kitamura T, Morita K, Tanaka K, Sekihara H 1999 Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection [see comments]. Intern Med 38:17-21.
9. Jensen RT 2000 Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment [review]. Curr Opin Oncol 12:368-377:
10. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R, Fehmann HC 2000 mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 30:729-739.
11. Bos JL 1989 ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689.
12. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M 1988 Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554.
13. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B 1987 Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297.
14. Rodenhuis S 1992 ras and human rumors. Sem Cancer Biol 3:241-247.
15. Ravi RK, Thiagalingam A, Weber E, McMahon M, Nelkin BD, Mabry M 1999 Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells [see comments]. Am J Respir Cell Mol Biol 20:543-549.
16. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, Pehamberger H, Gana-Weisz M, Ben David E, Kloog Y, Wolff K 1999 Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 96:14019-14024.
17. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW, Cordon-Cardo C, Yancopoulos GD, DePinho RA 1999 Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472.
18. Yashiro T, Fulton N, Hara H, Yasuda K, Montag A, Yashiro N, Straus F, Ito K, Aiyoshi Y, Kaplan EL 1993 Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114:758-763.
19. Younes N, Fulton N, Tanaka R, Wayne J, Straus FH, Kaplan EL 1997 The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 79:1804-1808.
20. Paraskevakou H, Saetta A, Skandalis K, Tseleni S, Athanassiadis A, Davaris PS 1999 Morphological-histochemical study of intestinal carcinoids and K-ras mutation analysis in appendiceal carcinoids. Pathol Oncol Res 5:205-210.
21. Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P, Gazdar AF 1999 Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85:600-607.
22. Lin SR, Tsai JH, Yang YC, Lee SC 1998 Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 77:1060-1065.
23. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL 1999 Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 22:781-789.
24. Nakagawa T, Mabry M, De Bustros A, Ihle JN, Nelkin BD, Baylin SB 1987 Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proc Natl Acad Sci USA 84:5923-5927.
25. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M 1997 Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17:5598-5611.
26. Bosch E, Cherwinski H, Peterson D, McMahon M 1997 Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Oncogene 15:1021-1033.
27. Zhu J, Woods D, McMahon M, Bishop JM 1998 Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12:2997-3007.
28. Carson EB, McMahon M, Baylin SB, Nelkin BD 1995 Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res 55:2048-2052.
29. Carson-Walter EB, Smith DP, Ponder BA, Baylin SB, Nelkin BD 1998 Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene 17:367-376.
30. Park JI, Strock CJ, Ball DW, Nelkin BD 2003 The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 23:543-554.
31. Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF 1998 Leukemia inhibitory factor: Part of a large ingathering family. Int Rev Immunol 16:397-426.
32. Auernhammer CJ, Melmed S 2000 Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21:313-345.
33. Broxmeyer HE 1994 Advances in understanding of biological effects of interleukin-11, leukemia inhibitory factor, and macrophage inflammatory protein 1 alpha. Curr Opin Hematol 1:197-202.
34. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ 2002 LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8:613-619.
35. Ball DW, Azzoli CG, Baylin SB, Chi D, Dou S, Donis-Keller H, Cumaraswamy A, Borges M, Nelkin BD 1993 Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci USA 90: 5648-5652.
36. Ball DW 2004 Achaete-scute homolog-1 and development Notch in lung neuroendocrine and cancer. Cancer Lett 204:159-169.
37. Lanigan TM, DeRaad SK, Russo AF 1998 Requirement of the MASH-1 transcription factor for neuroendocrine differentiation of thyroid C cells. J Neurobiol 34:126-134.
38. Guillemot F, Joyner AL 1993 Dynamic expression of the murine Achaete-Scute homologue Mash-1 in the developing nervous system. Mech Dev 42:171-185.
39. Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, Baylin SB, Ball DW 1997 An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386:852-855.
40. Chen H, Udelsman R, Zeiger MA, Ball DW 1997 Human achaete-scute homolog-1 is highly expressed in a subset of neuroendocrine tumors. Oncol Repo 4:775-778.
41. Chen H, Thiagalingam A, Chopra H, Borges MW, Feder JN, Nelkin BD, Baylin SB, Ball DW 1997 Conservation of the Drosophila lateral inhibition pathway in human lung cancer: A hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci USA 94:5355-5360.
42. Chen H, Carson-Walter EB, Baylin SB, Nelkin BD, Ball DW 1996 Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1. Surgery 120:168-172.
43. Sippel RS, Chen H 2002 Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation. Surgery 132:1035-1039.
44. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD, Mabry M 1998 Activated RaM causes growth arrest in human small cell lung cancer cells. J Clin Invest 101:153-159.
45. Artavanis-Tsakonas S, Rand MD, Lake RJ 1999 Notch signaling: Cell fate control and signal integration in development. Science 284:770-776.
46. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H 2003 The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 134:866-871.
47. Chen H, Biel MA, Borges MW, Thiagalingam A, Nelkin BD, Baylin SB, Ball DW 1997 Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: Transcriptional regulation by dual inhibitory regions. Cell Growth Differ 8:677-686.
48. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB, Nelkin BD 1999 Roles of trk family neurotrophin receptors in medullary thyroid-carcinoma development and progression. Proc Natl Acad Sci USA 96:4540-4545.
49. Liu Z, Falola J, Zhu X, Gu Y, Kim LT, Sarosi GA, Anthony T, Nwaariaku FE 2004 Anti-proliferative Effects of SRC Inhibition on Medullary Thyroid Cancer. J Clin Endocrinol Metab 89:3503-3509.